Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

Stock Information for Cyclerion Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cyclerion Therapeutics Inc.

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Regina Graul, Ph.D., Promoted to Chief Executive Officer
Cyclerion Appoints Regina Graul, Ph.D., as President
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
Cyclerion Announces Reverse Stock Split
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.